Cargando…
Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom
PURPOSE: Cicatrising conjunctival disorders are uncommon, and are difficult to diagnose and manage. This study was designed to assess the annual incidence and underlying diagnosis of patients with cicatrising conjunctivitis (CC) within the United Kingdom. METHODS: Clinical data of newly diagnosed ca...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443826/ https://www.ncbi.nlm.nih.gov/pubmed/22722485 http://dx.doi.org/10.1038/eye.2012.119 |
_version_ | 1782243606199795712 |
---|---|
author | Radford, C F Rauz, S Williams, G P Saw, V P J Dart, J K G |
author_facet | Radford, C F Rauz, S Williams, G P Saw, V P J Dart, J K G |
author_sort | Radford, C F |
collection | PubMed |
description | PURPOSE: Cicatrising conjunctival disorders are uncommon, and are difficult to diagnose and manage. This study was designed to assess the annual incidence and underlying diagnosis of patients with cicatrising conjunctivitis (CC) within the United Kingdom. METHODS: Clinical data of newly diagnosed cases of CC were reported via the British Ophthalmological Surveillance Unit at diagnosis and at 12 months follow-up. RESULTS: A total of 50 (61%) ocular mucous membrane pemphigoid (OcMMP), 16 (20%) Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS-TEN) and 16 (20%) other causes of CC, equating to an incidence of 0.8, 0.2, and 0.2 per million, respectively, were reported. Although diagnosis of SJS-TEN was usually within a median of 7 days of symptom-onset, that for OcMMP and other CC was a median 225 days for both. At diagnosis, 64/163 (39%) eyes had moderate/severe conjunctival inflammation, and 102/164 (62%) had symblepharon formation. Although 43/82 (52%) patients were commenced on immunosuppression or had this therapy modified, at follow-up there was an increase in the number of symblepharon, despite control of inflammation (P<0.001). Mortality only occurred in the SJS-TEN group (4/16 (25%)). CONCLUSION: CC has a substantial morbidity and for non-SJS-TEN causes, diagnosis is frequently delayed. The proportion of patients given immunosuppressive therapy to prevent disease progression may be less than optimal. These data highlight the need for developing patient access to specialist-designated centres with expertise in CC. |
format | Online Article Text |
id | pubmed-3443826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-34438262012-09-19 Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom Radford, C F Rauz, S Williams, G P Saw, V P J Dart, J K G Eye (Lond) Clinical Study PURPOSE: Cicatrising conjunctival disorders are uncommon, and are difficult to diagnose and manage. This study was designed to assess the annual incidence and underlying diagnosis of patients with cicatrising conjunctivitis (CC) within the United Kingdom. METHODS: Clinical data of newly diagnosed cases of CC were reported via the British Ophthalmological Surveillance Unit at diagnosis and at 12 months follow-up. RESULTS: A total of 50 (61%) ocular mucous membrane pemphigoid (OcMMP), 16 (20%) Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS-TEN) and 16 (20%) other causes of CC, equating to an incidence of 0.8, 0.2, and 0.2 per million, respectively, were reported. Although diagnosis of SJS-TEN was usually within a median of 7 days of symptom-onset, that for OcMMP and other CC was a median 225 days for both. At diagnosis, 64/163 (39%) eyes had moderate/severe conjunctival inflammation, and 102/164 (62%) had symblepharon formation. Although 43/82 (52%) patients were commenced on immunosuppression or had this therapy modified, at follow-up there was an increase in the number of symblepharon, despite control of inflammation (P<0.001). Mortality only occurred in the SJS-TEN group (4/16 (25%)). CONCLUSION: CC has a substantial morbidity and for non-SJS-TEN causes, diagnosis is frequently delayed. The proportion of patients given immunosuppressive therapy to prevent disease progression may be less than optimal. These data highlight the need for developing patient access to specialist-designated centres with expertise in CC. Nature Publishing Group 2012-09 2012-06-22 /pmc/articles/PMC3443826/ /pubmed/22722485 http://dx.doi.org/10.1038/eye.2012.119 Text en Copyright © 2012 Royal College of Ophthalmologists http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Clinical Study Radford, C F Rauz, S Williams, G P Saw, V P J Dart, J K G Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom |
title | Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom |
title_full | Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom |
title_fullStr | Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom |
title_full_unstemmed | Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom |
title_short | Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom |
title_sort | incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the united kingdom |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443826/ https://www.ncbi.nlm.nih.gov/pubmed/22722485 http://dx.doi.org/10.1038/eye.2012.119 |
work_keys_str_mv | AT radfordcf incidencepresentingfeaturesanddiagnosisofcicatrisingconjunctivitisintheunitedkingdom AT rauzs incidencepresentingfeaturesanddiagnosisofcicatrisingconjunctivitisintheunitedkingdom AT williamsgp incidencepresentingfeaturesanddiagnosisofcicatrisingconjunctivitisintheunitedkingdom AT sawvpj incidencepresentingfeaturesanddiagnosisofcicatrisingconjunctivitisintheunitedkingdom AT dartjkg incidencepresentingfeaturesanddiagnosisofcicatrisingconjunctivitisintheunitedkingdom |